MediBeacon receives regulatory approval to sell the Transdermal GFR System in China

NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc., a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, and an equity method investment of INNOVATE, has received approval from the National Medical Products Administration (NMPA) for Lumitrace^® (relmapirazin) injection, a non-radioactive, non-iodinated fluorescent GFR agent. Lumitrace will be sold as an integral component of the Transdermal GFR System in China.